Skip to main content
. 2022 Jan 4;28(8):1651–1661. doi: 10.1158/1078-0432.CCR-21-2855

Figure 4.

Figure 4. A, Fold changes in key metabolites identified by multivariate analysis concentrations in unwell patients with solid tumors relative to the mean metabolite concentrations in unwell patients without cancer. B, Fold changes in key metabolite concentrations in patients with metastatic cancer, relative to the mean metabolite concentration in patients with nonmetastatic cancer. C, Venn diagram illustrating direction of metabolite concentration changes in metastatic and nonmetastatic cancers, relative to unwell patients without cancer. HDL, high-density lipoprotein. Note that “/” represents that the two metabolites overlap in the NMR data, and not a ratio of the two metabolite concentrations. Individual plots of metabolite concentrations are given in Supplementary Fig. S4.

A, Fold changes in key metabolites identified by multivariate analysis concentrations in unwell patients with solid tumors relative to the mean metabolite concentrations in unwell patients without cancer. B, Fold changes in key metabolite concentrations in patients with metastatic cancer, relative to the mean metabolite concentration in patients with nonmetastatic cancer. C, Venn diagram illustrating direction of metabolite concentration changes in metastatic and nonmetastatic cancers, relative to unwell patients without cancer. HDL, high-density lipoprotein. Note that “/” represents that the two metabolites overlap in the NMR data, and not a ratio of the two metabolite concentrations. Individual plots of metabolite concentrations are given in Supplementary Fig. S4.